全文获取类型
收费全文 | 22253篇 |
免费 | 1677篇 |
国内免费 | 643篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 289篇 |
妇产科学 | 190篇 |
基础医学 | 1492篇 |
口腔科学 | 175篇 |
临床医学 | 1923篇 |
内科学 | 5163篇 |
皮肤病学 | 308篇 |
神经病学 | 1127篇 |
特种医学 | 306篇 |
外国民族医学 | 1篇 |
外科学 | 2459篇 |
综合类 | 1643篇 |
现状与发展 | 2篇 |
预防医学 | 672篇 |
眼科学 | 228篇 |
药学 | 5395篇 |
11篇 | |
中国医学 | 313篇 |
肿瘤学 | 2771篇 |
出版年
2024年 | 57篇 |
2023年 | 511篇 |
2022年 | 804篇 |
2021年 | 1070篇 |
2020年 | 1006篇 |
2019年 | 895篇 |
2018年 | 832篇 |
2017年 | 896篇 |
2016年 | 817篇 |
2015年 | 920篇 |
2014年 | 1243篇 |
2013年 | 2473篇 |
2012年 | 1155篇 |
2011年 | 1350篇 |
2010年 | 1012篇 |
2009年 | 1024篇 |
2008年 | 984篇 |
2007年 | 934篇 |
2006年 | 874篇 |
2005年 | 681篇 |
2004年 | 558篇 |
2003年 | 545篇 |
2002年 | 495篇 |
2001年 | 388篇 |
2000年 | 326篇 |
1999年 | 273篇 |
1998年 | 267篇 |
1997年 | 257篇 |
1996年 | 199篇 |
1995年 | 187篇 |
1994年 | 150篇 |
1993年 | 152篇 |
1992年 | 118篇 |
1991年 | 105篇 |
1990年 | 96篇 |
1989年 | 92篇 |
1988年 | 76篇 |
1987年 | 93篇 |
1986年 | 59篇 |
1985年 | 86篇 |
1984年 | 77篇 |
1983年 | 52篇 |
1982年 | 78篇 |
1981年 | 54篇 |
1980年 | 55篇 |
1979年 | 46篇 |
1978年 | 45篇 |
1977年 | 28篇 |
1976年 | 27篇 |
1973年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
Activated prothrombin complex concentrate (FEIBA® ) treatment during surgery in patients with inhibitors to FVIII/IX 总被引:1,自引:0,他引:1
Non-activated and activated prothrombin complex concentrates (PCC/aPCC) have been used successfully to treat bleeds in haemophilia patients with inhibitors, but most physicians do not consider these products as effective as factor VIII/IX (FVIII/IX) concentrates in non-inhibitor patients. Thus, surgical procedures in inhibitor patients have been performed reluctantly. We have performed 14 minor and five major surgical and invasive diagnostic procedures in eight patients with congenital haemophilia A and inhibitors and in two patients with acquired haemophilia. When a loading dose of 100 U kg-1 of FEIBA was given followed by 200 U kg-1 day-1 in three divided doses every 8 h for 3 days, and then, when the daily dose was tapered to 100-150 U kg-1, no severe or unexpected bleeding complications were observed. However, one adverse event was observed. A 69-year-old man who suffered a myocardial infarction the third postoperative day following sigmoidectomy was managed safely with opiate analgesia, nitrates and diuretics, and the continued use of FEIBA(R). 相似文献
53.
肝纤维化组织中MMP1、TIMP1的表达及其临床意义 总被引:2,自引:1,他引:1
目的 :检测肝纤维化组织中基质金属蛋白酶 1 (MMP1 )、基质金属蛋白酶组织抑制因子 1 (TIMP1 )的表达 ,为肝纤维化的诊治提供重要的分子生物学指标。 方法 :采用链霉菌抗生物蛋白 -过氧化酶联接法 (S- P法 )检测70例肝纤维化组织中 MMP1 、TIMP1 的表达。结果:(1) TIMP1 蛋白阳性表达随肝纤维化程度的加重而增强 ,并且呈正相关关系 (r=0 .92 74 ,P <0 .0 1)。 (2 ) MMP1 蛋白阳性表达随肝纤维化程度的加重无明显变化 ,无相关关系(r =0 .2 181,P >0 .0 5 )。 结论:TIMP1 与肝纤维化的发生、发展密切相关 ,随纤维化发生、发展阳性表达增强。从分子水平对肝纤维化、肝硬化病变进行评估 ,为早期诊治肝纤维化和判断预后提供依据。 相似文献
54.
全植入式药泵行肝血管灌注治疗晚期肝癌 总被引:6,自引:2,他引:4
对24例不能切除的晚期肝癌采用完全植入式药泵行肝动脉和门静脉双灌注化疗。结果:部分缓解(PR)15例(62.5%),稳定(S)8例(33.3%),进展(P)1例。平均生存期为9.17月,半年生存率为66.7%,1年为25%。在AFP>400μg/L的10例中,5例下降。 相似文献
55.
血卟啉衍生物(YHpD)合并照光对S180瘤细胞摄取~(86)Rb,瘤细胞的钠泵活性及糖酵解具有明显的抑制作用,且抑制程度随YHpD剂量的增大而增强。瘤细胞的总ATP酶和(Na-K)-ATP酶活性对YHpD的光动力效应也较敏感.YHpD对Mg—ATP酶活性有轻度抑制作用。YHpD并用哇巴因,对瘤细胞摄取~(86)Rb的光动力效应比两种药物单独应用的抑制作用大。 相似文献
56.
仇婷凤 《中国感染控制杂志》2003,2(3):193-194
目的 了解留置导尿所致尿路感染的发病率及影响因素。方法 采用前瞻性调查与回顾性调查相结合的方法,对妇产科手术后患者留置尿管而引发泌尿系感染率增高的原因进行调查和分析。结果 使用镇痛泵患者留置导尿后尿路感染率为5.45%,未用镇痛泵者的尿路感染率为0.21%,两者之间差异有高度显著性(P<0.005)。结论 镇痛泵不能滥用,使用时要避免诱发感染的因素。 相似文献
57.
The non-sulfhydryl selective angiotensin-converting enzyme inhibitor benazepril (20 mg daily) was compared with hydrochlorothiazide (50 mg daily) in post-infarction (6-24 months) patients with symptomatic (NYHA functional class 2) mild heart failure. No concomitant drug therapy was given. The study had a double-blind cross-over design with 3-month treatment periods. Both drugs were well tolerated, and both caused a similar reduction in systolic blood pressure. Heart rate was higher with the diuretic. Benazepril improved the NYHA functional class in 17 out of 29 (59%) patients, whereas one patient improved with hydrochlorothiazide (P = 0.0004). With regard to global efficacy score, benazepril was also superior. Thus, angiotensin-converting enzyme inhibitors may be superior to diuretics as first-choice therapy in symptomatic mild heart failure. 相似文献
58.
Seong‐II BIN Shing‐Sheng WU Xiaofeng ZENG Alan MOORE Nicole FRANK 《International journal of rheumatic diseases》2007,10(3):190-197
Aim: The aim of the current study was to assess the efficacy, safety, and tolerability of lumiracoxib 200 mg once daily (o.d.) in relieving osteoarthritis (OA) knee pain in patients in China, Taiwan, and South Korea. Methods: Patients of either sex (aged ≥ 18 years) with symptomatic, primary OA of the knee for ≥ 3 months were eligible for inclusion if they had OA pain intensity of ≥ 40 mm (100 mm visual analogue scale [VAS]) in the target knee joint during the previous 24 h. Patients were required to undergo regular non‐steroidal anti‐inflammatory drug therapy for ≥ 6 weeks. After 3–7 days of screening, patients were randomized (1 : 1) to receive either lumiracoxib 200 mg o.d. or celecoxib 200 mg o.d. The primary efficacy comparison between the study groups was overall OA pain intensity (VAS) in the target knee after 6 weeks of treatment. Results: The mean overall OA pain intensity (VAS) in the target knee after 6 weeks decreased from 60.6 mm to 35.7 mm and 60.5 mm to 36.1 mm in the lumiracoxib and celecoxib groups, respectively. Both study groups showed similar results in terms of improvement in both patient's and physician's global assessment of disease activity and functional health status. The percentage of adverse events (AEs) in the lumiracoxib and celecoxib groups (40.3% and 37.9%, respectively) was similar, as was the proportion of treatment‐related AEs (21.0% and 18.2%, respectively). Conclusions: Lumiracoxib 200 mg o.d. provided effective and well‐tolerated pain relief similar to that achieved with celecoxib 200 mg o.d. in knee OA patients. 相似文献
59.
60.
Alzheimer’s disease (AD) is the most common cause of dementia affecting nearly 18 million people around the world and 4.5 million in the US. It is a progressive neurodegenerative condition that is estimated to dramatically increase in prevalence as the elderly population continues to grow. As the cognitive and neuropsychiatric signs and symptoms of AD progresses in severity over time, affected individuals become increasingly dependent on others for assistance in performing all activities of daily living. The burden of caring for someone affected by the disorder is great and has substantial impact on a family’s emotional, social and financial well-being. In the US, the currently approved medications for the treatment of mild to moderate stages of AD are the cholinesterase inhibitors (ChEIs). Cholinesterase inhibitors have shown modest efficacy in terms of symptomatic improvement and stabilization for periods generally ranging from 6 to 12 months. There are additional data that have emerged, which suggest longer-term benefits. For the moderate to severe stages of AD, memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist is in widespread use and has shown modest benefit as monotherapy and in combination with ChEIs. The cost effectiveness of the currently available therapeutic agents for AD has undergone great scrutiny and remains controversial, especially outside the US. Neuropsychiatric symptoms such as agitation and psychosis are common in AD. Unfortunately, in the US there are no Food and Drug Administration (FDA)-approved agents for the treatment of these symptoms, although atypical antipsychotics have shown some efficacy and have been widely used. However, the use of these agents has recently warranted special caution due to reports of associated adverse effects such as weight gain, hyperlipidemia, glucose intolerance, cerebrovascular events, and an increased risk for death. Alternative agents used to treat neuropsychiatric symptoms include serotonergic antidepressants, benzodiazepines, and anticonvulsant medications. 相似文献